A significant increase in the mortality rate in the patients with heart failure (HF) have been witnessed. There is a great urgency to understand the pathophysiology underlying this exceedingly high mortality. The decision to treat patients with HF with antiplatelet therapy remains largely influenced by the presence or absence of concomitant arterial disease. Antithrombotic therapy has been shown to be effective in many forms of cardiac disease, including patients with HF and atrial fibrillation.
This article explores the potential role of antiplatelet function to improve outcomes in the HF patients. A major focus of HF research has been in the area of neurohormonal control and resynchronization therapy. HF is the next most frequent associated cardiac condition after atrial fibrillation. Although AF significantly increases the risk of stroke, the keen risk of thromboembolism in HF…
